Cosmo（CMOP.F）株式概要コスモ・ファーマシューティカルズN.V.は、世界中の消化器、皮膚科、ヘルステック向け製品の開発と商業化に注力している。 詳細CMOP.F ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長5/6過去の実績0/6財務の健全性4/6配当金2/6報酬当社が推定した公正価値より93.5%で取引されている 収益は年間55.11%増加すると予測されています リスク分析3.36%の配当は、利益やフリーキャッシュフローによって十分にカバーされていない すべてのリスクチェックを見るCMOP.F Community Fair Values Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.NEW478,064 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA478,064 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$75.0771.7% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-31m409m2016201920222025202620282031Revenue €408.8mEarnings €60.3mAdvancedSet Fair ValueView all narrativesCosmo N.V. 競合他社ApnimedSymbol: NasdaqGS:APMDMarket cap: US$1.3bWave Life SciencesSymbol: NasdaqGM:WVEMarket cap: US$1.1bPacira BioSciencesSymbol: NasdaqGS:PCRXMarket cap: US$916.8mTrulieve CannabisSymbol: NYSE:TRLVMarket cap: US$1.9b価格と性能株価の高値、安値、推移の概要Cosmo過去の株価現在の株価CHF 75.0752週高値CHF 169.9052週安値CHF 72.60ベータ1.481ヶ月の変化-2.63%3ヶ月変化-23.99%1年変化n/a3年間の変化n/a5年間の変化-16.95%IPOからの変化-53.28%最新ニュースお知らせ • Aug 13Cosmo Pharmaceuticals Reports 12-Month Phase 3 Results for Clascoterone 5% Topical Solution in Male Androgenetic AlopeciaCosmo Pharmaceuticals reported recent Phase 3 results for clascoterone 5% topical solution, an investigational treatment for male androgenetic alopecia. According to Cosmo Pharmaceuticals, the 12-month results from its SCALP 1 and SCALP 2 Phase 3 program showed a safety and tolerability profile comparable to vehicle and continued hair growth in patients who remained on treatment through one year. The company reported a statistically significant 2.39-fold improvement in target area hair count among patients who stayed on clascoterone for the full 12 months, compared with those who received the drug for six months and were then switched to vehicle. The program enrolled 1,465 men across 51 centers in the United States and Europe. Androgenetic alopecia, or male pattern hair loss, is the most common cause of hair loss in men. Cosmo reports that it affects roughly 40% of men worldwide and about 65 million men in the United States, yet the category has seen limited pharmaceutical innovation for decades. Clascoterone is designed to locally inhibit androgen receptor signaling in the scalp, targeting one of the biological drivers of follicle miniaturization. According to Cosmo, if approved it would be the first treatment with a novel mechanism of action for male androgenetic alopecia in more than 30 years. Clascoterone is the same active ingredient used in Winlevi, an approved topical acne treatment, which gives the molecule an established dermatologic safety record. The one-year findings come from an extension phase with a specific structure. Only patients who reported a positive response on the study's patient-reported outcome survey during the first six months continued into the second six-month period, where they were re-randomized to stay on clascoterone or switch to vehicle. That design is common in long-term dermatology trials and is consistent with FDA guidance on evaluating durability, but it means the 12-month results describe patients who had already shown a response rather than everyone who started treatment. Cosmo has said it is preparing regulatory submissions, with a U.S. FDA filing planned for early 2027, and intends to submit the full dataset for peer-reviewed publication and presentation at dermatology meetings.お知らせ • Mar 14Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026, at 12:00 W. Europe Standard Time.お知らせ • Feb 04Cosmo Pharmaceuticals N.V. announced that it has received funding from Capital Research and Management CompanyCosmo Pharmaceuticals N.V announced that it has completed a private placement with a single institutional investor and issued 937,086 treasury shares representing 5.3% of the company's outstanding shares on February 3, 2026. The transaction included participation from Small cap World Fund of the Capital Group.お知らせ • Jan 09+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2025 Final Results on Mar 09, 2026Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2025 final results on Mar 09, 2026お知らせ • Apr 30Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025.お知らせ • Apr 01Cosmo Pharmaceuticals N.V. Appoints Federico Sommariva as Chief Legal CounselCosmo Pharmaceuticals N.V. announced the appointment of Federico Sommariva as Chief Legal Counsel. Federico reports to the CEO and is member of the management team. Federico Sommariva has many years of legal and management experience in the Lifesciences industry. Since June 2013, he has worked for Gilead Sciences based in Milan (Italy), with increasing responsibilities. Most recently, he acted as Director and Global Legal Business Partner Oncology. He also served for 1.5 years as interim Head of Legal and Compliance for Gilead Sciences Romania. Federico studied law at the University of Milan and started his professional career as Legal Counsel Secondee at H&M in Rome (Italy).最新情報をもっと見るRecent updatesお知らせ • Aug 13Cosmo Pharmaceuticals Reports 12-Month Phase 3 Results for Clascoterone 5% Topical Solution in Male Androgenetic AlopeciaCosmo Pharmaceuticals reported recent Phase 3 results for clascoterone 5% topical solution, an investigational treatment for male androgenetic alopecia. According to Cosmo Pharmaceuticals, the 12-month results from its SCALP 1 and SCALP 2 Phase 3 program showed a safety and tolerability profile comparable to vehicle and continued hair growth in patients who remained on treatment through one year. The company reported a statistically significant 2.39-fold improvement in target area hair count among patients who stayed on clascoterone for the full 12 months, compared with those who received the drug for six months and were then switched to vehicle. The program enrolled 1,465 men across 51 centers in the United States and Europe. Androgenetic alopecia, or male pattern hair loss, is the most common cause of hair loss in men. Cosmo reports that it affects roughly 40% of men worldwide and about 65 million men in the United States, yet the category has seen limited pharmaceutical innovation for decades. Clascoterone is designed to locally inhibit androgen receptor signaling in the scalp, targeting one of the biological drivers of follicle miniaturization. According to Cosmo, if approved it would be the first treatment with a novel mechanism of action for male androgenetic alopecia in more than 30 years. Clascoterone is the same active ingredient used in Winlevi, an approved topical acne treatment, which gives the molecule an established dermatologic safety record. The one-year findings come from an extension phase with a specific structure. Only patients who reported a positive response on the study's patient-reported outcome survey during the first six months continued into the second six-month period, where they were re-randomized to stay on clascoterone or switch to vehicle. That design is common in long-term dermatology trials and is consistent with FDA guidance on evaluating durability, but it means the 12-month results describe patients who had already shown a response rather than everyone who started treatment. Cosmo has said it is preparing regulatory submissions, with a U.S. FDA filing planned for early 2027, and intends to submit the full dataset for peer-reviewed publication and presentation at dermatology meetings.お知らせ • Mar 14Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026, at 12:00 W. Europe Standard Time.お知らせ • Feb 04Cosmo Pharmaceuticals N.V. announced that it has received funding from Capital Research and Management CompanyCosmo Pharmaceuticals N.V announced that it has completed a private placement with a single institutional investor and issued 937,086 treasury shares representing 5.3% of the company's outstanding shares on February 3, 2026. The transaction included participation from Small cap World Fund of the Capital Group.お知らせ • Jan 09+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2025 Final Results on Mar 09, 2026Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2025 final results on Mar 09, 2026お知らせ • Apr 30Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025.お知らせ • Apr 01Cosmo Pharmaceuticals N.V. Appoints Federico Sommariva as Chief Legal CounselCosmo Pharmaceuticals N.V. announced the appointment of Federico Sommariva as Chief Legal Counsel. Federico reports to the CEO and is member of the management team. Federico Sommariva has many years of legal and management experience in the Lifesciences industry. Since June 2013, he has worked for Gilead Sciences based in Milan (Italy), with increasing responsibilities. Most recently, he acted as Director and Global Legal Business Partner Oncology. He also served for 1.5 years as interim Head of Legal and Compliance for Gilead Sciences Romania. Federico studied law at the University of Milan and started his professional career as Legal Counsel Secondee at H&M in Rome (Italy).お知らせ • Feb 11Cosmo Pharmaceuticals N.V. Announces the Appointment of Andrea Cherubini as Chief AI OfficerCosmo Pharmaceuticals N.V. announced the appointment of Andrea Cherubini as Chief AI Officer effective immediately. This important decision reflects Cosmo's commitment to integrating Artificial Intelligence as a core strategic pillar in its future growth and innovation roadmap. Andrea will report to the CEO and will be member of the executive leadership team. Andrea has been pivotal in the development and commercialization of Cosmo's GI GeniusT. As Senior Vice President - Science, AI, and Data, he was leading the development of innovative AI solutions for the Cosmo Intelligent Medical Devices division since 2018. His extensive clinical expertise, data-driven approach, and leadership in AI have already transformed patient outcomes, showcasing the real-world impact of AI in medical applications. AI as a Strategic Growth Driver In his new role as Chief AI Officer, Andrea will spearhead the expansion of AI beyond endoscopy, embedding it across Cosmo's entire portfolio to accelerate innovation, enhance efficiencies, and unlock new value for both patients and shareholders. This includes, among others: Gastroenterology Pipeline - Advancing AI applications in drug development, particularly for Bile Acid Diarrhea (BAD), to drive precision medicine and predictive analytics in GI disorders. Dermatology Pipeline - Leveraging AI to optimize clinical trial design, patient selection, and personalized treatment pathways for Breezula and other dermatological innovations. AI-Enabled Drug Discovery & Development - Expanding AI's role in R&D, regulatory strategies, and digital health applications, reinforcing Cosmo's position as a leader in AI-driven healthcare solutions. At the same time, Andrea will continue to play a critical role in shaping Cosmo's Intelligent Medical Devices division's AI roadmap, reinforcing GI GeniusT as the leading real-time AI platform in endoscopy.お知らせ • Jan 21+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Results on Mar 06, 2025Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 results on Mar 06, 2025お知らせ • Jan 08Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Final Results on Mar 20, 2025Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 final results at 12:00 PM, Central European Standard Time on Mar 20, 2025お知らせ • Oct 12Cosmo Pharmaceuticals N.V. Announces Chief Financial Officer ChangesCosmo Pharmaceuticals N.V. announced the appointment of Svetlana Sigalova as its new Chief Financial Officer, effective November 11, 2024. Svetlana will succeed Niall Donnelly, who has served as CFO since 2016. Svetlana Sigalova brings a wealth of expertise from her time at Moderna, where she served as Vice President of Commercial Finance and led the financial operations for over $6 billion in global sales. Her proven ability to develop financial infrastructure and planning systems was pivotal in Moderna's rapid growth during the pandemic. Prior to Moderna, Svetlana held senior finance leadership positions at Alexion Pharmaceuticals and Vertex Pharmaceuticals, where she managed multibillion-dollar revenue streams, built high-performance finance teams, and drove operational efficiency. Niall will transition to a strategic new role as EVP - Corporate Governance & Chief Sustainability Officer, where he will report to CEO and play a key part in strengthening Cosmo's corporate governance framework and driving the Company's mission to advance environmental, social, and governance (ESG) initiatives. With a focus on achieving carbon footprint reduction and sustainable business practices, Niall's leadership will ensure Cosmo continues to build a strong and responsible organization with a robust governance structure that aligns with the Company's long-term growth and value creation. He will also remain an executive member of the Board of Directors of Cosmo.お知らせ • Apr 28Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024Cosmo Pharmaceuticals N.V. announced the appointment of Giovanni Di Napoli as its new Chief Executive Officer, along with changes to its Board of Directors, at the upcoming Annual General Meeting (AGM) on 24 May 2024. At the same time, it will be proposed at the AGM to appoint longstanding Cosmo CEO Alessandro Della Cha as the new Chairman of Cosmo. Alessandro joined Cosmo in 2006 as member of the Board of Directors and was appointed as CEO of the Company in 2014. Giovanni is an accomplished leader with an excellent track record and joins Cosmo from Medtronic where he held various leadership positions since 2008. Until recently, Giovanni was President of Medtronic's Endoscopy Operating Unit located in Santa Clara, California. In this position, he and his team were responsible for one of the most innovative and fast-growing portfolios in the endoscopy market, which included technologies such as Endoflip, Pillcam, and GI Genius. From July 2017 to November 2020, he was Vice President and General Manager GIH - Gastrointestinal and Hepatology and was Vice President Sales U.S. - GI Solutions from February 2015 to July 2017. From April 2012 to February 2015, he was Director of Sales Marketing for Western Europe. Previously, Giovanni held various leadership positions at Johnson Johnson Medical (2001- 2010). Giovanni has an MBA from the Universita Bocconi, Milan, Italy.お知らせ • Mar 22Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2023 Final Results on Apr 30, 2024Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2023 final results on Apr 30, 2024お知らせ • Feb 15Cosmo Pharmaceuticals N.V. to Report First Half, 2024 Results on Jul 25, 2024Cosmo Pharmaceuticals N.V. announced that they will report first half, 2024 results on Jul 25, 2024お知らせ • Dec 06+ 1 more updateCosmo Pharmaceuticals N.V., Annual General Meeting, May 24, 2024Cosmo Pharmaceuticals N.V., Annual General Meeting, May 24, 2024.お知らせ • Dec 20+ 2 more updatesCosmo Pharmaceuticals N.V., Annual General Meeting, May 26, 2023Cosmo Pharmaceuticals N.V., Annual General Meeting, May 26, 2023.株主還元CMOP.FUS PharmaceuticalsUS 市場7D-0.3%0.6%0.6%1Yn/a49.9%20.1%株主還元を見る業界別リターン: CMOP.FがUS Pharmaceuticals業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: CMOP.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is CMOP.F's price volatile compared to industry and market?CMOP.F volatilityCMOP.F Average Weekly Movement6.5%Pharmaceuticals Industry Average Movement9.0%Market Average Movement7.1%10% most volatile stocks in US Market16.3%10% least volatile stocks in US Market3.1%安定した株価: CMOP.F 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: CMOP.Fの 週次ボラティリティ ( 7% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1997365Giovanni Di Napoliwww.cosmohealthconfidence.comコスモ・ファーマシューティカルズN V.は、消化器病学、皮膚病学、ヘルステック向けの製品の開発と商業化に世界中で注力している。同社は、人工知能をリアルタイムで使用して大腸病変を検出するコンピュータ支援システムGIジーニアス、尋常性ざ瘡の治療に皮膚に使用する処方薬ウィンレビ、活動性の軽度から中等度の潰瘍性大腸炎を寛解に導くために承認された1日1回投与のメサラミン錠剤リアルダ／メザバント／メサバンコール、ブデソニドを大腸内腔に直接送達する経口錠剤ユセリス／コルチメントを提供している；Eleview：内視鏡医が消化管病変をより迅速かつ低リスクで切除できるようにする注射用組成物、Lumeblue：大腸内視鏡検査時に大腸病変を可視化する診断薬、Aemcolo/Relafalk：旅行者下痢症の治療薬として承認された錠剤医薬品、Byfavo：ベンゾジアゼピン系鎮静・麻酔薬の静脈内投与。また、頭皮のアンドロゲン受容体をターゲットとする新規アンドロゲン受容体阻害剤Breezulaを開発中で、第III相臨床試験中である。遠位潰瘍性大腸炎および直腸炎の治療薬として第II相臨床試験中のリファマイシン1％浣腸薬も開発中である；胆汁酸性下痢治療薬として前臨床試験中のコルセベラム、固形癌治療薬として第I相臨床試験中の経口アンドロゲン受容体・グルココルチコイド受容体拮抗薬コルテキソロン17a-バレレート-21-プロピオネート、またコスモ社のAI技術であるGIジーニアスインテリジェント内視鏡システムを提供している。同社は、ボシュ・ヘルス社、フェリング社、チャイナ・メディカル・システム・ホールディングス社、メドトロニック社、レッドヒル・バイオファーマ社、サン・ファーマシューティカル・インダストリーズ社、3Sバイオ社、インフェクトファーマ社、ハイフェンズ・ファーマ・インターナショナル社と開発、販売、ライセンス契約を結んでいる。コスモ・ファーマシューティカルズN.V.は1997年に設立され、アイルランドのダブリンに本社を置いている。もっと見るCosmo N.V. 基礎のまとめCosmo の収益と売上を時価総額と比較するとどうか。CMOP.F 基礎統計学時価総額US$1.24b収益（TTM）-US$7.36m売上高(TTM)US$118.96m10.5xP/Sレシオ-169.0xPER（株価収益率CMOP.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CMOP.F 損益計算書（TTM）収益€102.69m売上原価€55.95m売上総利益€46.74mその他の費用€53.09m収益-€6.35m直近の収益報告Jun 30, 2026次回決算日該当なし一株当たり利益（EPS）-0.37グロス・マージン45.51%純利益率-6.19%有利子負債／自己資本比率0.05%CMOP.F の長期的なパフォーマンスは？過去の実績と比較を見る配当金3.4%現在の配当利回り-546%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/17 13:25終値2026/08/13 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cosmo N.V. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11 アナリスト機関Estelle BétriseyBerenbergLaura HindleyBerenbergKerry HolfordBerenberg8 その他のアナリストを表示
お知らせ • Aug 13Cosmo Pharmaceuticals Reports 12-Month Phase 3 Results for Clascoterone 5% Topical Solution in Male Androgenetic AlopeciaCosmo Pharmaceuticals reported recent Phase 3 results for clascoterone 5% topical solution, an investigational treatment for male androgenetic alopecia. According to Cosmo Pharmaceuticals, the 12-month results from its SCALP 1 and SCALP 2 Phase 3 program showed a safety and tolerability profile comparable to vehicle and continued hair growth in patients who remained on treatment through one year. The company reported a statistically significant 2.39-fold improvement in target area hair count among patients who stayed on clascoterone for the full 12 months, compared with those who received the drug for six months and were then switched to vehicle. The program enrolled 1,465 men across 51 centers in the United States and Europe. Androgenetic alopecia, or male pattern hair loss, is the most common cause of hair loss in men. Cosmo reports that it affects roughly 40% of men worldwide and about 65 million men in the United States, yet the category has seen limited pharmaceutical innovation for decades. Clascoterone is designed to locally inhibit androgen receptor signaling in the scalp, targeting one of the biological drivers of follicle miniaturization. According to Cosmo, if approved it would be the first treatment with a novel mechanism of action for male androgenetic alopecia in more than 30 years. Clascoterone is the same active ingredient used in Winlevi, an approved topical acne treatment, which gives the molecule an established dermatologic safety record. The one-year findings come from an extension phase with a specific structure. Only patients who reported a positive response on the study's patient-reported outcome survey during the first six months continued into the second six-month period, where they were re-randomized to stay on clascoterone or switch to vehicle. That design is common in long-term dermatology trials and is consistent with FDA guidance on evaluating durability, but it means the 12-month results describe patients who had already shown a response rather than everyone who started treatment. Cosmo has said it is preparing regulatory submissions, with a U.S. FDA filing planned for early 2027, and intends to submit the full dataset for peer-reviewed publication and presentation at dermatology meetings.
お知らせ • Mar 14Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026, at 12:00 W. Europe Standard Time.
お知らせ • Feb 04Cosmo Pharmaceuticals N.V. announced that it has received funding from Capital Research and Management CompanyCosmo Pharmaceuticals N.V announced that it has completed a private placement with a single institutional investor and issued 937,086 treasury shares representing 5.3% of the company's outstanding shares on February 3, 2026. The transaction included participation from Small cap World Fund of the Capital Group.
お知らせ • Jan 09+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2025 Final Results on Mar 09, 2026Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2025 final results on Mar 09, 2026
お知らせ • Apr 30Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025.
お知らせ • Apr 01Cosmo Pharmaceuticals N.V. Appoints Federico Sommariva as Chief Legal CounselCosmo Pharmaceuticals N.V. announced the appointment of Federico Sommariva as Chief Legal Counsel. Federico reports to the CEO and is member of the management team. Federico Sommariva has many years of legal and management experience in the Lifesciences industry. Since June 2013, he has worked for Gilead Sciences based in Milan (Italy), with increasing responsibilities. Most recently, he acted as Director and Global Legal Business Partner Oncology. He also served for 1.5 years as interim Head of Legal and Compliance for Gilead Sciences Romania. Federico studied law at the University of Milan and started his professional career as Legal Counsel Secondee at H&M in Rome (Italy).
お知らせ • Aug 13Cosmo Pharmaceuticals Reports 12-Month Phase 3 Results for Clascoterone 5% Topical Solution in Male Androgenetic AlopeciaCosmo Pharmaceuticals reported recent Phase 3 results for clascoterone 5% topical solution, an investigational treatment for male androgenetic alopecia. According to Cosmo Pharmaceuticals, the 12-month results from its SCALP 1 and SCALP 2 Phase 3 program showed a safety and tolerability profile comparable to vehicle and continued hair growth in patients who remained on treatment through one year. The company reported a statistically significant 2.39-fold improvement in target area hair count among patients who stayed on clascoterone for the full 12 months, compared with those who received the drug for six months and were then switched to vehicle. The program enrolled 1,465 men across 51 centers in the United States and Europe. Androgenetic alopecia, or male pattern hair loss, is the most common cause of hair loss in men. Cosmo reports that it affects roughly 40% of men worldwide and about 65 million men in the United States, yet the category has seen limited pharmaceutical innovation for decades. Clascoterone is designed to locally inhibit androgen receptor signaling in the scalp, targeting one of the biological drivers of follicle miniaturization. According to Cosmo, if approved it would be the first treatment with a novel mechanism of action for male androgenetic alopecia in more than 30 years. Clascoterone is the same active ingredient used in Winlevi, an approved topical acne treatment, which gives the molecule an established dermatologic safety record. The one-year findings come from an extension phase with a specific structure. Only patients who reported a positive response on the study's patient-reported outcome survey during the first six months continued into the second six-month period, where they were re-randomized to stay on clascoterone or switch to vehicle. That design is common in long-term dermatology trials and is consistent with FDA guidance on evaluating durability, but it means the 12-month results describe patients who had already shown a response rather than everyone who started treatment. Cosmo has said it is preparing regulatory submissions, with a U.S. FDA filing planned for early 2027, and intends to submit the full dataset for peer-reviewed publication and presentation at dermatology meetings.
お知らせ • Mar 14Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026, at 12:00 W. Europe Standard Time.
お知らせ • Feb 04Cosmo Pharmaceuticals N.V. announced that it has received funding from Capital Research and Management CompanyCosmo Pharmaceuticals N.V announced that it has completed a private placement with a single institutional investor and issued 937,086 treasury shares representing 5.3% of the company's outstanding shares on February 3, 2026. The transaction included participation from Small cap World Fund of the Capital Group.
お知らせ • Jan 09+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2025 Final Results on Mar 09, 2026Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2025 final results on Mar 09, 2026
お知らせ • Apr 30Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025.
お知らせ • Apr 01Cosmo Pharmaceuticals N.V. Appoints Federico Sommariva as Chief Legal CounselCosmo Pharmaceuticals N.V. announced the appointment of Federico Sommariva as Chief Legal Counsel. Federico reports to the CEO and is member of the management team. Federico Sommariva has many years of legal and management experience in the Lifesciences industry. Since June 2013, he has worked for Gilead Sciences based in Milan (Italy), with increasing responsibilities. Most recently, he acted as Director and Global Legal Business Partner Oncology. He also served for 1.5 years as interim Head of Legal and Compliance for Gilead Sciences Romania. Federico studied law at the University of Milan and started his professional career as Legal Counsel Secondee at H&M in Rome (Italy).
お知らせ • Feb 11Cosmo Pharmaceuticals N.V. Announces the Appointment of Andrea Cherubini as Chief AI OfficerCosmo Pharmaceuticals N.V. announced the appointment of Andrea Cherubini as Chief AI Officer effective immediately. This important decision reflects Cosmo's commitment to integrating Artificial Intelligence as a core strategic pillar in its future growth and innovation roadmap. Andrea will report to the CEO and will be member of the executive leadership team. Andrea has been pivotal in the development and commercialization of Cosmo's GI GeniusT. As Senior Vice President - Science, AI, and Data, he was leading the development of innovative AI solutions for the Cosmo Intelligent Medical Devices division since 2018. His extensive clinical expertise, data-driven approach, and leadership in AI have already transformed patient outcomes, showcasing the real-world impact of AI in medical applications. AI as a Strategic Growth Driver In his new role as Chief AI Officer, Andrea will spearhead the expansion of AI beyond endoscopy, embedding it across Cosmo's entire portfolio to accelerate innovation, enhance efficiencies, and unlock new value for both patients and shareholders. This includes, among others: Gastroenterology Pipeline - Advancing AI applications in drug development, particularly for Bile Acid Diarrhea (BAD), to drive precision medicine and predictive analytics in GI disorders. Dermatology Pipeline - Leveraging AI to optimize clinical trial design, patient selection, and personalized treatment pathways for Breezula and other dermatological innovations. AI-Enabled Drug Discovery & Development - Expanding AI's role in R&D, regulatory strategies, and digital health applications, reinforcing Cosmo's position as a leader in AI-driven healthcare solutions. At the same time, Andrea will continue to play a critical role in shaping Cosmo's Intelligent Medical Devices division's AI roadmap, reinforcing GI GeniusT as the leading real-time AI platform in endoscopy.
お知らせ • Jan 21+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Results on Mar 06, 2025Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 results on Mar 06, 2025
お知らせ • Jan 08Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Final Results on Mar 20, 2025Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 final results at 12:00 PM, Central European Standard Time on Mar 20, 2025
お知らせ • Oct 12Cosmo Pharmaceuticals N.V. Announces Chief Financial Officer ChangesCosmo Pharmaceuticals N.V. announced the appointment of Svetlana Sigalova as its new Chief Financial Officer, effective November 11, 2024. Svetlana will succeed Niall Donnelly, who has served as CFO since 2016. Svetlana Sigalova brings a wealth of expertise from her time at Moderna, where she served as Vice President of Commercial Finance and led the financial operations for over $6 billion in global sales. Her proven ability to develop financial infrastructure and planning systems was pivotal in Moderna's rapid growth during the pandemic. Prior to Moderna, Svetlana held senior finance leadership positions at Alexion Pharmaceuticals and Vertex Pharmaceuticals, where she managed multibillion-dollar revenue streams, built high-performance finance teams, and drove operational efficiency. Niall will transition to a strategic new role as EVP - Corporate Governance & Chief Sustainability Officer, where he will report to CEO and play a key part in strengthening Cosmo's corporate governance framework and driving the Company's mission to advance environmental, social, and governance (ESG) initiatives. With a focus on achieving carbon footprint reduction and sustainable business practices, Niall's leadership will ensure Cosmo continues to build a strong and responsible organization with a robust governance structure that aligns with the Company's long-term growth and value creation. He will also remain an executive member of the Board of Directors of Cosmo.
お知らせ • Apr 28Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024Cosmo Pharmaceuticals N.V. announced the appointment of Giovanni Di Napoli as its new Chief Executive Officer, along with changes to its Board of Directors, at the upcoming Annual General Meeting (AGM) on 24 May 2024. At the same time, it will be proposed at the AGM to appoint longstanding Cosmo CEO Alessandro Della Cha as the new Chairman of Cosmo. Alessandro joined Cosmo in 2006 as member of the Board of Directors and was appointed as CEO of the Company in 2014. Giovanni is an accomplished leader with an excellent track record and joins Cosmo from Medtronic where he held various leadership positions since 2008. Until recently, Giovanni was President of Medtronic's Endoscopy Operating Unit located in Santa Clara, California. In this position, he and his team were responsible for one of the most innovative and fast-growing portfolios in the endoscopy market, which included technologies such as Endoflip, Pillcam, and GI Genius. From July 2017 to November 2020, he was Vice President and General Manager GIH - Gastrointestinal and Hepatology and was Vice President Sales U.S. - GI Solutions from February 2015 to July 2017. From April 2012 to February 2015, he was Director of Sales Marketing for Western Europe. Previously, Giovanni held various leadership positions at Johnson Johnson Medical (2001- 2010). Giovanni has an MBA from the Universita Bocconi, Milan, Italy.
お知らせ • Mar 22Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2023 Final Results on Apr 30, 2024Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2023 final results on Apr 30, 2024
お知らせ • Feb 15Cosmo Pharmaceuticals N.V. to Report First Half, 2024 Results on Jul 25, 2024Cosmo Pharmaceuticals N.V. announced that they will report first half, 2024 results on Jul 25, 2024
お知らせ • Dec 06+ 1 more updateCosmo Pharmaceuticals N.V., Annual General Meeting, May 24, 2024Cosmo Pharmaceuticals N.V., Annual General Meeting, May 24, 2024.
お知らせ • Dec 20+ 2 more updatesCosmo Pharmaceuticals N.V., Annual General Meeting, May 26, 2023Cosmo Pharmaceuticals N.V., Annual General Meeting, May 26, 2023.
